Browsing by Author "Rajesh, R"

Now showing 1 - 3 of 3
  • Item
    Evaluation of lauryl chitosan graft polyethyleneimine as a potential carrier of genes and anticancer drugs
    (PROCESS BIOCHEMISTRY, 2012) Rajesh, R; Rekha, MR; Sharma, CP
    The conjugation of bioactive molecules to polymeric nanocarriers has the potential to revolutionize current methods of cancer therapy. These nanocarriers can also reduce the undesirable adverse effects of small molecule therapeutic agents. In the present study, the LC-g-PEI (lauryl chitosan graft polyethyleneimine) polymer was synthesized and evaluated as a potential carrier of therapeutic molecules, such as the p53 gene and doxorubicin. The study was designed to investigate the cytotoxicity, drug uptake and transfection efficiency of LC-g-PEI. This polymer had lower interactions with blood components than the unmodified PEI. LC-g-PEI buffered protons, protected DNA from nuclease attack and induced effective gene transfer in the C6 cell line. LC-g-PEI that had incorporated doxorubicin exhibited an enhanced release of this compound at pH 5. LC-g-PEI demonstrated its efficacy in the enhancement of drug uptake and the promotion of gene expression in the C6 cell line. Therefore, LC-g-PEI shows promise as a drug/gene carrier with potential applications in cancer therapy. (c) 2012 Elsevier Ltd. All rights reserved.
  • Item
  • Item
    Prenatal screening for neural tube defects
    (NATIONAL MEDICAL JOURNAL OF INDIA, 2001)
    Neural tube defects are common birth defects with a prevalence of 4-15 per 10 000 live-births. Prenatal diagnosis of neural tube defects has Implications in obstetric management and many countries have successfully reduced their Incidence by adopting nationwide preventive programmes. It is generally accepted that failure of the neural tube to close causes these defects. Periconceptional use of antiepileptic drugs such as valproate and carbamazepine and deficiency of folate Is associated with a hi Incidence of these defects. Procedures for prenatal diagnosis Include: (i) assessment of serum markers such as maternal serum alpha-foetoprotein and acetylcholinesterase activity; (ii) prenatal ultrasonography; and (iii) amniocentesis In selected cases. The levels of these two serum markers are increased In neural tube defects and a value of more than two multiples of the median Is considered significant. The optimal time for serum screening Is 10-18 weeks. In the case of serum markers it is Important to apply normative data standardized for a laboratory and the duration of gestation. Antenatal ultrasonography is a simple, non-invasive and widely available test which has a similar sensitivity with lower false positivity compared to serum markers. Early diagnosis by ultrasound demands skill and experience In the procedure. Levels of amniotic fluid alpha-foetoprotein and acetylcholinesterase activity are elevated In neural tube defects. However, increased iatrogenic foetal loss Is a disadvantage of this technique. Detailed counselling of the couple needs to be an integral part of the prenatal screening programme.